102792-04-1

Upstream product

• 306937-14-4 (4-bromo-2-methylphenyl)carbamic acid tert-butyl ester 
• 288-13-1 NH-pyrazole 
• 446-33-3 5-Fluoro-2-nitrotoluene 
• 102792-12-1 1-(3-methyl-4-nitrophenyl)-1H-pyrazole 

Downstream Products

• 727993-19-3 3-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}ethyl)-6-methyl-N-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-4-[3-(1,3-thiazol-2-yl)-1H-pyrazol-1-yl]-2-pyridinamine 
• 1059734-51-8 N-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide 

Relevant academic research and scientific papers

INHIBITORS OF THE HEDGEHOG PATHWAY

The present invention is directed to a compound of Formula (I) or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula (I) to treat cancer.

HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).

2(1H)-Quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five membered heteroaryl) derivatives

A series of 6-(N-linked, five membered heteroaryl)-2(1H)-quinolinone derivatives was synthesized and evaluated for cardiotonic activity. Most compounds were prepared by sulfuric acid catalyzed cyclization of an N-(4-heteroarylphenyl)-3-ethoxypropenamide o